Concepedia

Bryan W. Sherman

BW

7

Publications

448

Citations

7

H-Index

2001

Active since

Affiliations

Research Triangle Park Foundation(Current)

GlaxoSmithKline (United States)

Aerie Pharmaceuticals (United States)

Bryan W. Sherman is an author at Research Triangle Park Foundation specializing in medicine, drug discovery, and pharmacology.

Top concepts

Publications per year

2001–2017

7

Publications

7

Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma

Cheng‐Wen Lin, Bryan W. Sherman, Lori Moore et al. · Journal of Ocular Pharmacology and Therapeutics · 2017 · 181 citations · Full text

Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma

Jill M. Sturdivant, Susan M. Royalty, Cheng‐Wen Lin et al. · Bioorganic & Medicinal Chemistry Letters · 2016 · 104 citations · Full text

, , +6

Synthesis and Evaluation of Potent and Selective β<sub>3</sub> Adrenergic Receptor Agonists Containing Acylsulfonamide, Sulfonylsulfonamide, and Sulfonylurea Carboxylic Acid Isosteres

David Uehling, Kelly H. Donaldson, David N. Deaton et al. · Journal of Medicinal Chemistry · 2001 · 62 citations · Full text

, , +12

Biarylaniline Phenethanolamines as Potent and Selective β<sub>3</sub>Adrenergic Receptor Agonists

David Uehling, Barry G. Shearer, Kelly H. Donaldson et al. · Journal of Medicinal Chemistry · 2006 · 41 citations · Full text

, , +14

2-(Anilinomethyl)imidazolines as α<sub>1</sub> Adrenergic Receptor Agonists:  the Discovery of α<sub>1</sub><sub>a</sub> Subtype Selective 2‘-Alkylsulfonyl-Substituted Analogues

Stephen J. Hodson, Michael J. Bishop, Jason D. Speake et al. · Journal of Medicinal Chemistry · 2002 · 25 citations · Full text

, , +13

Rows per page

1–5 of 7